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Pancreatic cystic and neoplasms are being diagnosed with increasing frequency. Accurate
diagnosis and determination of benign versus malignant lesions is crucial for determining
need for surveillance versus surgery or endoscopic therapy as well as avoiding unnec-
essary surgery in cysts with no malignant potential. Tumor markers such as KRAS and
GNAS hold promise, but which molecular marker or a combination of markers is most
useful and cost effective remains to be seen. Advanced imaging with confocal laser
endomicroscopy can serve as an optical biopsy and play a part in the diagnostic algo-
rithm. Microforceps aided biopsy of pancreatic cyst wall and tumor contents hold great
promise as they allow direct tissue acquisition. Much progress has been made in the role
of EUS guided evaluation of pancreatic cystic neoplasms over the last several years, and
with the advances enumerated above, the future is more than just a few shades of gray.
Future studies should include prospective multi-arm trials of microforceps biopsy versus
conventional EUS-FNA and use of biochemical and molecular markers, confocal laser
endomicroscopy or a combination thereof to determine best approach to pancreatic cystic
neoplasms. In Osler's words, ‘Medicine is a science of uncertainty and an art of proba-
bility’. Incorporation of advanced imaging and molecular markers into a new diagnostic
algorithm with subsequent validation through retrospective and prospective studies has
the potential to increase diagnostic accuracy and guide optimal management of patients
and improve outcomes.1. Introduction
Ever since the advent of endoscopic ultrasound in the 1980s,
the scope of EUS guided interventions has broadened in parallel
to technical advances such as reﬁnement in image quality and
better understanding of the endosonographic anatomy.
Today, a repertoire of more than a dozen therapeutic in-
terventions exist in the advanced endoscopist's armamentarium
for diagnosis, staging and treatment of pancreato-biliary and
other gastrointestinal malignancies as well as benign conditions.
EUS is routinely used today in clinical practice for staging of
esophageal, gastric, colonic as well as pancreatic and biliarytumors. EUS-FNA and core biopsies form some of the standard
diagnostic interventions aided by EUS. More recent advances in
technology have the potential to take the diagnostic and thera-
peutic value of EUS to a higher level, allowing for more diag-
nostic accuracy and broader range of therapeutic interventions.
2. Role of EUS-FNA and new biochemical and
molecular markers obtained by cyst ﬂuid aspiration
in diagnosis of pancreatic cystic neoplasms
EUS-FNA has already been established to be superior to
multi-detector CT for diagnosis of pancreatic neoplasms less
than 2 cm in size in patients with clinical symptoms suggestive
of malignancy but a negative CT scan [1].
EUS not only helps in assessing size, extent and features con-
cerning for malignancy such as ductal dilation, mural nodules and
vascular invasion [2], but it also allows for sampling the cyst for on
site cytology as well for obtaining markers such as CEA, which is
presently the most commonly utilized biochemical marker across
the United States [3]. Worthy of mentioning here is thes article under the CC BY-NC-ND license (http://
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that CEA was the only tumor marker useful for distinguishing
mucinous cysts from non mucinous cysts, when the level
was>192 ng/mL, although the sensitivity was only 73% [4].
Apart from EUS-FNA and core biopsies, a cytobrush is
available to increase the cellular yield from pancreatic cystic
lesions. Indeed, a prospective study involving tandem EUS-FNA
and EUS guided cytobrushings showed that the yield of intra-
cellular mucin was signiﬁcantly more with cytobrushings [5].
Another study showed a statistically proven superiority of
EUS guided cytology brushings over ﬂuid aspiration [6],
however the complication rate in this small study was
unacceptably high with cytobrushings, limiting its use.
As an adjunct to cytology, there has been an interest in the
diagnostic utility of biomarkers from cyst ﬂuid [7]. A recent
multicenter center using a panel of biomarkers showed that
serous cystadenomas could be identiﬁed with a sensitivity of
100% and speciﬁcity of 91% by presence of the marker VHL
and chromosome 3 LOH and by the absence of a KRAS,
GNAS, RNF43 mutation or by the absence of aneuploidy in
chromosome 5p or 8p [8].
IPMNs were identiﬁed with 76% sensitivity and 97% spec-
iﬁcity by the presence of a mutation in GNAS, RNF43, LOH in
chromosome 9, aneuploidy in chromosome 1q or 8p [8]. Solid
pseudopapillary tumors were identiﬁed with 100% sensitivity
and 100% speciﬁcity by the presence of a CTNNB1 mutation
and the absence of KRAS, GNAS, or RNF43 mutations or
chromosome 18 LOH [8]. Tumor markers could alleviate some
of the diagnostic roadblocks encountered when cellularity
from EUS-FNA is inadequate or the cytology read is indeter-
minate for dysplasia.
3. Safety of EUS guided sampling
EUS-FNA breaches the gut wall barrier and there is potential
for adverse events such as bleeding, perforation, infection and
concern for peritoneal seeding from malignant cystic neoplasms.
EUS-FNA, however, has been established to be very safe, with
overall adverse event rate ranging from 0% to 2.5% [9].
Even though EUS guided cytobrush sampling has proved to
give much higher yields and provide an accurate diagnosis, we
currently do not recommend it given the risk of unacceptably
high complications of 10%, including one death due to delayed
retroperitoneal hemorrhage in one patient to date [5].
There has been concern for peritoneal seeding from FNA in
IPMNs which harbor malignancy, however the PIPE study
showed no signiﬁcant different in rate of peritoneal seeding
when compared to patients who had surgery for pancreatic cystic
lesions but who did not undergo preoperative EUS guided
sampling [10].
4. Real time ‘optical diagnosis’ of pancreatic cystic
neoplasms using needle based confocal laser
endomicroscopy
Optical diagnosis of lesions with malignant potential remains
the holy grail of advanced imaging techniques. Recent ad-
vancements have allowed a small needle based confocal endo-
microscopy probe (nCLE) (AQ Flex 19, Mauna Kea
technologies, Paris, France) to be passed through the 19 G EUS-
FNA needle [11].The INSPECT and DETECT trial require special mention
here. The INSPECT trial, was a pilot study involving 8 centers
using nCLE and it established descriptive terminologies for
imaging ﬁndings on nCLE obtained from the pancreatic paren-
chyma, epithelial cyst structures and from the cyst lumen. Ex-
amples of descriptive terms include ‘ﬁnger like papillary
projections’ and ‘dark aggregates of cells’. This study also
established their histopathologic co-relates and demonstrated a
100% PPV in identifying IPMNs when ‘villous structures’ were
seen on nCLE [12].
A subsequent study, called the DETECT trial utilized probe
based pancreatic cystoscopy using direct visualization with
Spyglass (Spyglass DS, Boston Scientiﬁc, USA) combined with
nCLE and showed that the combination of mucin on Spyglass
cystoscopy and papillary projections or dark rings on nCLE had
a sensitivity of 93% and speciﬁcity of 88% for diagnosis of
mucinous cysts in patient with high certainty diagnosis, which
was deﬁned as cases where surgical pathology was not available
but two independent investigators agreed with a concordant
diagnosis [13].
5. EUS guided chemical ablation of pancreatic cystic
lesions
For patients with pancreatic cysts that merit surgical resection
but who are poor surgical candidates, EUS guided chemical
ablation remains a theoretically appealing alternative due to the
morbidity associated with pancreatic surgery [14].
Ethanol alone and ethanol followed by paclitaxel have been
commonly used agents with success rate ranging from 38% to
79%, deﬁned as complete resolution of cystic lesions [15,16].
Complications of this technique range from mild abdominal
pain to pancreatitis and even portal vein thrombosis [17].
Several prior studies assessing response of ethanol injection
or lavage did not standardize the technique and ethanol con-
centration or volume of ethanol instilled into the cyst cavity.
A recent ten year prospective study by Topazian et al.
showed that EUS guided ethanol lavage showed dismal results
with respect to complete ablation of pancreatic cyst, as seen by
complete resolution of cysts in only 9% of patients [18]. Thus,
EUS guided chemoablation of pancreatic cystic neoplasms in
carefully selected non-surgical candidates may be attempted,
however the data is less than promising and search for better
non-surgical ablative techniques is warranted.
6. EUS-guided RFA of pancreatic lesions
Radiofrequency ablation is well established for eradication of
dysplastic Barrett's esophagus as well as hepatocellular carci-
noma, however, the use of EUS-RFA for ablation of pancreatic
cystic lesions is still in the realm of case reports and pilot studies
and may become more popular if future studies show promising
data.
A South Korean study of 6 patients with unresectable
pancreatic cancer demonstrated that RFA of pancreatic tumors
through an EUS guided approach was feasible, and aside from
abdominal pain that could be controlled with analgesics, there
were no adverse events such as pancreatitis, bleeding, duodenal
injury, or portal vein or splenic vein thrombosis [19].
EUS guided RFA holds promise in ablation of discrete le-
sions such as neuroendocrine tumors of the pancreas in patients
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comorbidities. Indeed, a recent study by Lakhtakia et al. showed
successful RFA of symptomatic insulinomas smaller than
22 mm in three patients who remained symptom free at 11–12
month follow up along with biochemical improvement in fasting
insulin and blood sugar levels [20].
EUS guided RFA may be an option not only for solid lesions
but cystic pancreatic neoplasms as well. A recent prospective
multicenter study involving 6 patients undergoing RFA of
pancreatic cystic neoplasms showed complete resolution of
PCNs in 33%, or two patients and 48.4% reduction in size in
three other patients [21].
Further research should involve prospective studies recruiting
more number of patients and follow them up for a longer
duration to assess the true efﬁcacy of EUS-RFA.
7. EUS guided microforceps biopsy of pancreatic
cystic and solid neoplasms
Tissue biopsy remains the gold standard for an accurate
pathologic diagnosis. However, limitations of technology meant
that endosonographers have to rely on aspiration of cellular el-
ements at FNA for more than two decades or on core biopsies.
Developments in device miniaturization may change the current
standard approach. Recently developed miniforceps (Moray, US
Endoscopy, Ohio, USA and Endoﬂex GmbH, Voerde, Ger-
many) can pass through the lumen of a 19 G FNA needle may
allow better tissue acquisition. A few recent case reports have
shown promise where mucinous pancreatic neoplasms were
diagnosed on the basis of tissue biopsy of pancreatic cysts using
microforceps [22–24]. More studies will clearly be needed but this
is a welcome development.
8. Which gastroenterology society guidelines should
one follow for pancreatic cystic lesion management
and follow up?
The working group of the eleventh congress of the Interna-
tional Association of Pancreatology held in Sendai, Japan in
2004 came up with guidelines, informally referred to as the
‘Sendai Criteria’ in endoscopy parlance. These were updated in
2012, and are aptly called the International Consensus guide-
lines, rather than evidence-based guidelines since the level of
evidence on the recommendations was low. These are
commonly referred to as the ‘Fukuoka guidelines’. A detailed
discussion on these guidelines is beyond the scope of this
commentary, but these brieﬂy deﬁned three ‘high risk stigmata’
which include obstructive jaundice, enhancing solid component
a cyst and main pancreatic duct diameter >10 mm and ﬁve
‘worrisome features’ which include cyst >3 cm, thickened or
enhancing cyst walls, main duct size (5–9) mm, non-enhancing
mural nodule and abrupt change in caliber of pancreatic duct
with distal pancreatic atrophy [25].
The 2012 Fukuoka International Consensus Guidelines
have been lauded by several subsequent studies. A retrospec-
tive study from Japan from 2014 showed that multivariate
analysis identiﬁed obstructive jaundice (OR = 23.9;
P < 0.0001), abrupt change in MPD diameter (OR = 3.01;
P = 0.017) and lymphadenopathy (OR = 5.84; P = 0.027) as
independent predictive factors, with an accuracy of 69.8, 67.4,
and 66.3%, respectively [26].Surgical literature from Singapore from 2014 shows that the
PPV of the high risk criteria for detecting HGD or carcinoma
was 62.5% and the NPV of the low risk group was 100% [27].
The American Gastroenterology Association also recently
proposed practice guidelines on management of PCNs [28].
These however have come under criticism because of a lack
of distinction between mucinous cystadenomas and IPMNs,
discontinuation of surveillance and lack of use of molecular
markers [29]. Not enough studies are available yet that can
validate the AGA guidelines fully. In our opinion, until more
data becomes available, a judicious approach in keeping with
the Fukuoka guidelines and consideration of patient's age,
comorbidities, family history of pancreatic cancer or other
genetic cancer syndromes and locally available endoscopy and
surgical expertise is advised.
9. Conclusions
Pancreatic cystic and neoplasms are being diagnosed with
increasing frequency [30]. Accurate diagnosis and determination
of benign versus malignant lesions is crucial for determining
need for surveillance versus surgery or endoscopic therapy as
well as avoiding unnecessary surgery in cysts with no
malignant potential. Tumor markers such as KRAS and GNAS
hold promise, but which molecular marker or a combination of
markers is most useful and cost effective remains to be seen.
Advanced imaging with confocal laser endomicroscopy can
serve as an optical biopsy and play a part in the diagnostic
algorithm. Microforceps aided biopsy of pancreatic cyst wall
and tumor contents hold great promise as they allow direct
tissue acquisition. Much progress has been made in the role of
EUS guided evaluation of pancreatic cystic neoplasms over the
last several years [31], and with the advances enumerated
above, the future is more than just a few shades of gray.
Future studies should include prospective multi-arm trials of
microforceps biopsy versus conventional EUS-FNA and use of
biochemical and molecular markers, confocal laser endomicro-
scopy or a combination thereof to determine best approach to
pancreatic cystic neoplasms. In Osler's words, ‘Medicine is a
science of uncertainty and an art of probability’. Incorporation of
advanced imaging and molecular markers into a new diagnostic
algorithm with subsequent validation through retrospective and
prospective studies has the potential to increase diagnostic ac-
curacy and guide optimal management of patients and improve
outcomes.
Conﬂict of interest statement
We declare that we have no conﬂict of interest.
References
[1] Wang W, Shpaner A, Krishna SG, Ross WA, Bhutani MS,
Tamm EP, et al. Use of EUS-FNA in diagnosing pancreatic
neoplasm without a deﬁnitive mass on CT. Gastrointest Endosc
2013; 78(1): 73-80.
[2] Hijioka S, Hara K, Mizuno N, Imaoka H, Bhatia V, Yamao K.
Morphological differentiation and follow-up of pancreatic cystic
neoplasms using endoscopic ultrasound. Endosc Ultrasound 2015;
4(4): 312-318.
[3] Alkaade S, Chahla E, Levy M. Role of endoscopic ultrasound-
guided ﬁne-needle aspiration cytology, viscosity, and
Tejas Kirtane, Manoop S. Bhutani/Asian Paciﬁc Journal of Tropical Medicine 2016; 9(12): 1218–1221 1221carcinoembryonic antigen in pancreatic cyst ﬂuid. Endosc Ultra-
sound 2015; 4(4): 299-303.
[4] Brugge WR, Lewandrowski K, Lee-Lewandrowski E,
Centeno BA, Szydlo T, Regan S, et al. Diagnosis of pancreatic
cystic neoplasms: a report of the cooperative pancreatic cyst study.
Gastroenterology 2004; 126(5): 1330-1336.
[5] Al-Haddad M, Gill KR, Raimondo M, Woodward TA, Krishna M,
Crook JE, et al. Safety and efﬁcacy of cytology brushings versus
standard ﬁne-needle aspiration in evaluating cystic pancreatic le-
sions: a controlled study. Endoscopy 2010; 42(2): 127-132.
[6] Sendino O, Fernandez-Esparrach G, Sole M, Colomo L, Pellise´ M,
Llach J, et al. Endoscopic ultrasonography-guided brushing in-
creases cellular diagnosis of pancreatic cysts: a prospective study.
Dig Liver Dis 2010; 42(12): 877-881.
[7] Al-Haddad M. Role of emerging molecular markers in pancreatic
cyst ﬂuid. Endosc Ultrasound 2015; 4(4): 276-283.
[8] Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I,
et al. A combination of molecular markers and clinical features
improve the classiﬁcation of pancreatic cysts. Gastroenterology
2015; 149(6): 1501-1510.
[9] Yoon WJ, Brugge WR. The safety of endoscopic ultrasound-
guided ﬁne-needle aspiration of pancreatic cystic lesions. Endosc
Ultrasound 2015; 4(4): 289-292.
[10] Yoon WJ, Daglilar ES, Fernandez-del Castillo C, Mino-
Kenudson M, Pitman MB, Brugge WR. Peritoneal seeding in
intraductal papillary mucinous neoplasm of the pancreas patients
who underwent endoscopic ultrasound-guided ﬁne-needle aspira-
tion: the PIPE study. Endoscopy 2014; 46(5): 382-387.
[11] Giovannini M. Needle-based confocal laser endomicroscopy.
Endosc Ultrasound 2015; 4(4): 284-288.
[12] Konda VJ, Meining A, Jamil LH, Giovannini M, Hwang JH,
Wallace MB, et al. A pilot study of in vivo identiﬁcation of
pancreatic cystic neoplasms with needle-based confocal laser
endomicroscopy under endosonographic guidance. Endoscopy
2013; 45(12): 1006-1013.
[13] Nakai Y, Iwashita T, Park do H, Samarasena JB, Lee JG, Chang KJ.
Diagnosis of pancreatic cysts: EUS-guided, through-the-needle
confocal laser-induced endomicroscopy and cystoscopy trial:
DETECT study. Gastrointest Endosc 2015; 81(5): 1204-1214.
[14] Cho MK, Choi JH, Seo DW. Endoscopic ultrasound-guided abla-
tion therapy for pancreatic cysts. Endosc Ultrasound 2015; 4(4):
293-298.
[15] DiMaio CJ, DeWitt JM, Brugge WR. Ablation of pancreatic cystic
lesions: the use of multiple endoscopic ultrasound-guided ethanol
lavage sessions. Pancreas 2011; 40(5): 664-668.
[16] Oh HC, Seo DW, Lee TY, Kim JY, Lee SS, Lee SK, et al. New
treatment for cystic tumors of the pancreas: EUS-guided ethanol
lavage with paclitaxel injection. Gastrointest Endosc 2008; 67(4):
636-642.
[17] Oh HC, Seo DW, Kim SC. Portal vein thrombosis after EUS-
guided pancreatic cyst ablation. Dig Dis Sci 2012; 57(7): 1965-
1967.
[18] Gomez V, Takahashi N, Levy MJ, McGee KP, Jones A, Huang YJ,
et al. EUS-guided ethanol lavage does not reliably ablate pancreatic
cystic neoplasms (with video). Gastrointest Endosc 2016; 83(5):
914-920.[19] Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh DW, Park do H,
et al. Initial experience of EUS-guided radiofrequency ablation of
unresectable pancreatic cancer. Gastrointest Endosc 2016; 83(2):
440-443.
[20] Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cicinnati VR,
et al. Endoscopic ultrasound guided radiofrequency ablation, for
pancreatic cystic neoplasms and neuroendocrine tumors. World J
Gastrointest Surg 2015; 7(4): 52-59.
[21] Lakhtakia S, Ramchandani M, Galasso D, Gupta Rajesh,
Venugopal Sushma, Kalpala Rakesh, et al. EUS-guided radio-
frequency ablation for management of pancreatic insulinoma by
using a novel needle electrode (with videos). Gastrointest Endosc
2016; 83(1): 234-239.
[22] Pham KD, Engjom T, Gjelberg Kollesete H, Helgeland L. Diag-
nosis of a mucinous pancreatic cyst and resection of an intracystic
nodule using a novel through-the-needle micro forceps. Endoscopy
2016; 48(Suppl 1): E125-E126.
[23] Barresi L, Tarantino I, Ligresti D, Curcio G, Granata A, Traina M.
A new tissue acquisition technique in pancreatic cystic neoplasm:
endoscopic ultrasound-guided through-the-needle forceps biopsy.
Endoscopy 2015; 47(Suppl 1): E297-E298. UCTN.
[24] Samarasena JB, Nakai Y, Shinoura S, Lee JG, Chang KJ. EUS-
guided, through-the-needle forceps biopsy: a novel tissue acquisi-
tion technique. Gastrointest Endosc 2015; 81(1): 225-226.
[25] Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M,
Jang JY, et al. International consensus guidelines 2012 for the
management of IPMN and MCN of the pancreas. Pancreatology
2012; 12(3): 183-197.
[26] Yamada S, Fujii T, Murotani K, Kanda M, Sugimoto H,
Nakayama G, et al. Comparison of the international consensus
guidelines for predicting malignancy in intraductal papillary
mucinous neoplasms. Surgery 2016; 159(3): 878-884.
[27] Goh BK, Thng CH, Tan DM, Low AS, Wong JS, Cheow PC, et al.
Evaluation of the sendai and 2012 international consensus guide-
lines based on cross-sectional imaging ﬁndings performed for the
initial triage of mucinous cystic lesions of the pancreas: a single
institution experience with 114 surgically treated patients. Am J
Surg 2014; 208(2): 202-209.
[28] Vege SS, Ziring B, Jain R, Moayyedi P, Clinical Guidelines
Committee, American Gastroenterology Association. American
gastroenterological association institute guideline on the diagnosis
and management of asymptomatic neoplastic pancreatic cysts.
Gastroenterology 2015; 148(4): 819-822.
[29] Singhi AD, Zeh HJ, Brand RE, Nikiforova MN, Chennat JS,
Fasanella KE, et al. American Gastroenterological Association
guidelines are inaccurate in detecting pancreatic cysts with
advanced neoplasia: a clinicopathologic study of 225 patients with
supporting molecular data. Gastrointest Endosc 2016; 83(6): 1107-
1117.
[30] Lu X, Zhang S, Ma C, Peng C, Lv Y, Zou X. The diagnostic value
of EUS in pancreatic cystic neoplasms compared with CT and
MRI. Endosc Ultrasound 2015; 4(4): 324-329.
[31] Hocke M, Cui XW, Domagk D, Ignee A, Dietrich CF. Pancreatic
cystic lesions: the value of contrast-enhanced endoscopic ultra-
sound to inﬂuence the clinical pathway. Endosc Ultrasound 2014;
3(2): 123-130.
